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Although natalizumab (anti-𝛼4 integrin) represents an effective therapy for relapsing remitting multiple sclerosis (RRMS), it is
associated with an increased risk of developing progressive multifocal leukoencephalopathy (PML), caused by the polyomavirus JC
(JCV).The aim of this study was to explore natalizumab-induced phenotypic changes in peripheral blood T-lymphocytes and their
relationship with JCV reactivation. Forty-four patients affected by RRMS were enrolled. Blood and urine samples were classified
according to natalizumab infusion number: 0 (𝑁0), 1–12 (𝑁12), 13–24 (𝑁24), 25–36 (𝑁36), and over 36 (𝑁 > 36) infusions. JCV-
DNA was detected in plasma and urine. T-lymphocyte phenotype was evaluated with flow cytometry. JCV serostatus was assessed.
Ten healthy donors (HD), whose ages and sexes matched with the RRMS patients of the 𝑁0 group, were enrolled. CD8 effector
(CD8 E) percentages were increased in natalizumab treated patients with detectable JCV-DNA in plasma or urine compared to
JCV-DNA negative patients (JCV−) (𝑝 < 0.01 and 𝑝 < 0.001, resp.). Patients with CD8 E percentages above 10.4% tended to show
detectable JCV-DNA in plasma and/or urine (ROC curve 𝑝 = 0.001). The CD8 E was increased when JCV-DNA was detectable
in plasma or urine, independently from JCV serology, for 𝑁12 and 𝑁24 groups (𝑝 < 0.01). As long as PML can affect RRMS
patients under natalizumab treatment with a negative JCV serology, the assessment of CD8 E could help in the evaluation of JCV
reactivation.
1. Introduction
More than 2.3 million people worldwide are living with
multiple sclerosis (MS) [1], a chronic inflammatory demyeli-
nating disease of the central nervous system (CNS) [2] with
85–90% of cases presenting as a relapsing remitting (RR)
form [1]. Lymphocyte migration through the blood brain
barrier (BBB) represents a crucial step in the process that
leads to inflammation and demyelination in the CNS [3].
The adhesion and subsequent migration of leukocytes into
the CNS are regulated by the molecular interaction between
membrane receptors and their cognate ligands, which are
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expressed on endothelial cell surface. Specifically, lymphocyte
migration into the CNS is regulated by the interaction of the
𝛼4𝛽1 integrin (very late antigen [VLA]-4), expressed on their
surface, with the vascular-cell adhesion molecule (VCAM)-
1, expressed on the vascular endothelial cell surface of CNS
blood vessels [4, 5]. Natalizumab (Tysabri; Biogen Idec, Cam-
bridge,MA,USA), a humanizedmonoclonal antibody target-
ing the 𝛼4 integrin (CD49d), was developed to inhibit leuko-
cyte adhesion to the vascular endothelium of the CNS [4,
6]. Consequently, natalizumab limits leukocyte recruitment
in the CNS, reducing the inflammation responsible for MS
lesions [7].
Natalizumab is a highly effective therapy for RRMS
characterized by a significant reduction in the relapse rate and
risk of disability progression [8, 9]. However, this treat-
ment is associated with an increased risk of progressive
multifocal leukoencephalopathy (PML), caused by the John
Cunningham polyomavirus (JCV) reactivation. Although
natalizumabwas initially approved for RRMS by the US Food
and Drug Administration (FDA) in 2004 [10, 11], in 2005 it
was temporarily withdrawn from the market because of the
occurrence of three cases of PML (two patients with MS and
one with Crohn’s disease) [12–14].
Factors associated with increased risk of developing PML
are (1) long-termnatalizumab treatment (beyond 24months),
(2) prior immunosuppressive treatment for MS, and (3) JCV
positive serology (assessed with the Stratify JCV test) [15].
However, the presence of anti-JCV antibodies was neither
diagnostic nor prognostic for PML, considering that patients
with negative serology for JCV can develop PML [16].
Several studies showed that natalizumab treatment affects
lymphocyte circulating subsets, increasing the pool of T-
cells and other lymphocytes in peripheral blood [17–19] and
modifying T-cell balance with an increased activation state
and potential to produce proinflammatory cytokines [17, 20,
21]. A few studies have addressed the issue of immunologic
changes related to JCV reactivation and PML onset [17, 22,
23].
The aim of this study was to describe natalizumab-
induced phenotypic changes in peripheral blood T-lym-
phocytes and their relationship with JCV reactivation, with
particular interest for JCV seronegative subjects.
2. Materials and Methods
2.1. Study Population. Patients affected by RRMS, followed
up at the Department of Neurology and Psychiatry of the
University of Rome “Sapienza,” were enrolled from March
2013 to March 2016. All patients were under a natalizumab-
based treatment and regularly underwent a complete physical
and neurological examination. Neurological disability was
assessed with the Expanded Disability Status Scale (EDSS)
score.
This study was approved by the Ethics Committee of
Policlinico Umberto I of Rome (protocol number 130/13).
All participants fulfilled the Italian Agency of Drug (AIFA)
criteria for natalizumab treatment and provided a written
informed consent before enrollment.
2.2. Sample Collection. Urine and blood were collected from
RRMS patients before natalizumab administration. Samples
were grouped according to the number of natalizumab infu-
sions, in the following groups: before starting the treatment
(𝑁0), from 1 to 12 infusions (𝑁12), from 13 to 24 infusions
(𝑁24), from 25 to 36 infusions (𝑁36), and over 36 infusions
(𝑁 > 36). Ten healthy donors (HD), whose ages and sexes
matched with the RRMS patients of the 𝑁0 group, were
enrolled as control group.
Whole blood was collected in ethylenediaminetetraacetic
acid (EDTA) and heparin tubes. Serum was obtained from
blood collected in tubes without anticoagulants, after cen-
trifugation, and stored at −80∘C. Plasma and peripheral
blood mononuclear cells (PBMC) were isolated from EDTA
whole blood via Ficoll Histopaque (Amersham Biosciences,
Uppsala, Sweden) density gradient centrifugation. The num-
ber of viable leukocytes was determined by trypan blue
exclusion. Plasma andPBMCwere stored at−80∘C.Urinewas
collected in sterile screw-cap containers and stored at −80∘C.
Heparin whole blood was used for multicolor flow cytometry
immunophenotyping.
2.3. Serological and Virological Analysis. The presence of
JCV specific antibodies in the serum of RRMS patients
was assessed after the activation of the Stratify JCV service,
supported by Biogen Idec, using the Stratify JCV assay, a two-
step enzyme-linked immunosorbent assay, able to detect anti-
JCV specific IgG. Both first-generation (Stratify JCV assay,
Focus Diagnostics, Cypress, CA) and second-generation
(Stratify JCV DxSelect, Focus Diagnostics, Cypress, CA)
assays were used to detect anti-JCV antibodies in this cohort
of patients, according to enrollment date and test availability.
Viral DNA was extracted from plasma and urine samples
with the DNeasy Blood & Tissue Kit (QIAGEN, S.p.A, Milan,
Italy), according to the manufacturer’s instructions, and the
extraction productwas analyzedwith a real time PCR (qPCR)
system to detect and quantify a 54-bp amplicon in the JCV T
antigen region using a 7300 real time PCR system (Applied
Biosystems, USA). The viral load results have been reported
as the mean of two positive reactions for each sample, and
the JCV-DNA load in plasma and urine specimens has been
expressed as genome equivalents (gEq)/milliliter of sample.
Negative and positive controls have been included in each
qPCR session. Standard curve was obtained from serial
dilutions (range: 105–102 gEq/mL) of a plasmid containing
the entire JCV genome [24]. The lower detection limit of the
qPCR systemwas 10DNA copies of the target gene per ampli-
fication reaction, corresponding to 10 genome equivalents
per reaction (10 gEq/reaction).
JCV-DNA positive samples were further analyzed using a
nested PCR system for the amplification of the hypervariable
noncoding control region (NCCR) in order to confirm the
positivity obtained with the real time system, thus increasing
specificity [24].
2.4. T-Lymphocyte Analysis. Immunofluorescence stainings
for CD4+ and CD8+ T-lymphocyte subsets, immune acti-
vation and senescence, were performed according to a lyse-
and-wash protocol using heparin whole blood samples.
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Table 1: Demographic and clinical features of HD and RRMS patients.
HD RRMS patients
𝑁0 𝑁12 𝑁24 𝑁36 𝑁 > 36
𝑁 15 19 29 32 12 6
F/M 7/8 7/12 13/17 17/14 8/4 2/4
Median age in years [IQR] 30 [27–35] 29.5 [26–38] 46.5 [37–50.3] 40 [38–42.5] 38 [29–40] 40.5 [33.5–47.5]
Median years of disease [IQR] - 7.5 [5.2–9.7] 11.5 [9.2–18.7] 14 [8–23] 9 [7.25–11.7] 7 [6–9.5]
Median EDSS∗ [IQR] - 2 [0.5–2] 1 [1–1.5] 2.5 [2.1–2.8] 1 [1-2] 1 [1–1.75]
No therapy∗∗ (/N) - 4/19 6/29 8/32 4/12 4/6
Interferon 𝛽∗∗ (/N) - 13/19 20/29 19/32 7/12 2/6
Mitoxantrone and interferon 𝛽∗∗ (/N) - 1/19 1/29 1/32 0/12 0/6
Glatiramer acetate∗∗ (/N) - 1/19 2/29 4/32 1/12 0/6
HD: healthy donors,𝑁0: 0 infusions,𝑁12: from 1 to 12 infusions,𝑁24: from 13 to 24 infusions,𝑁36: from 25 to 36 infusions, and𝑁 > 36: over 36 infusions
of natalizumab.𝑁: total number of patients; F: female; M: male; IQR: interquartile range; ∗EDSS: Expanded Disability Status Scale, with values ranging from
0 (normal neurological examination) to 10 (bedridden patient) (1); ∗∗therapy before starting natalizumab.
Briefly, T-cell immune activation was assessed measuring
the percentages of double positive HLA-DR and CD38
cells, while immune senescence was assessed measuring the
percentages of CD28 negative and CD57 positive cells for
both CD3+CD4+ and CD3+CD8+ T-lymphocytes. In order
to evaluate T-lymphocyte subsets, CD4 and CD8 subpop-
ulations were defined according to CD27 and CD45RO
expressions, as follows: naı¨ve (N: CD27+CD45RO−), central
memory (CM: CD27+CD45RO+), effector memory (EM:
CD27−CD45RO+), effector (E: CD27−CD45RO−), and, only
for CD8, intermediate (I: CD27lowCD45RO−). Flow cytom-
etry staining protocols and analyses have been thoroughly
described in detail elsewhere [17].
2.5. Data Analysis and Statistics. Flow cytometry data were
analyzed using FlowJo Software v. 10. Statistical analyses were
performed using GraphPad Prism version 6. The 2-tailed 𝜒2
test or Fisher’s exact test was used for comparing proportions.
The Mann–Whitney and Kruskal–Wallis tests were used for
comparing medians. Differences were considered significant
if 𝑝 ≤ 0.05.
3. Results
3.1. Study Population. Forty-four patients (24 females, 20
males) with clinically defined RRMS were included in
the study. Median age [interquartile range (IQR)] was 38
[32.5–44.5]. Median [IQR] years of disease were 9 [7–14].
Before starting natalizumab, 61.4% of patients (27/44) had
been treated with interferon 𝛽, 11.4% (5/44) with glatiramer
acetate, and 4.5% (2/44) with mitoxantrone and interferon 𝛽,
and 22.7% (10/44) had not received any previous treatment.
The median [IQR] EDSS value was 2 [1-2]. Ten HD (5
females, 5 males), whose ages and sexes matched with
RRMS patients of the 𝑁0 group, were enrolled as control
group.
A total of 262 samples were collected from 44 RRMS
patients (131 urine and 131 blood samples). Demographic
and clinical features of all RRMS patients are shown in
Table 1.
3.2. Comparison between JCV-DNA Detection and Stratify
JCVAssay Results. Positivity rate of anti-JCV antibody detec-
tion was 42.1% (8/19), 30% (15/50), 40.5% (17/42), 50%
(7/14), and 83.3% (5/6) for 𝑁0, 𝑁12, 𝑁24, 𝑁36, and 𝑁 >
36, respectively (Supplementary Table 1). No statistically
significant differences were found comparing the 5 groups of
RRMS patients (2-tailed 𝜒2-square test).
JCV-DNA was detected with qPCR in urine and plasma.
JCV-DNA positivity rate in urine was 15.8% (3/19), 20%
(10/50), 21.4% (9/42), 14.3% (2/14), and 16.7% (1/6), while in
plasma it was 26.3% (5/19), 16% (8/50), 26.2% (11/42), 28.6%
(4/14), and 16.7% (1/6) of cases for 𝑁0, 𝑁12, 𝑁24, 𝑁36, and
𝑁 > 36, respectively. Combining plasma and urine JCV-
DNA detection results, the positivity rate was 42.1% (8/19),
24% (12/50), 33.3% (14/42), 42.8% (6/14), and 33.3% (2/6) of
cases for 𝑁0, 𝑁12, 𝑁24, 𝑁36, and 𝑁 > 36, respectively.
No statistically significant differences were found comparing
the 5 groups in the three settings (urine, blood, or urine and
blood) (2-tailed 𝜒2 test).
At each sampling time, JCV serology and JCV-DNA
detection in plasma and urine were compared. If JCV-DNA
was detected either in plasma, urine, or both samples the
patient was defined as JCV-DNA+ for that specific time point.
Conversely, the patient was defined as JCV-DNA− if JCV-
DNA was undetectable in all the samples analyzed for a
specific time point.
Comparing JCV serostatus and JCV-DNA detection in
the 5 groups, a subset of patients with discordant results
(JCV-DNA detection with a negative JCV serostatus) was
identified: 21.1% (4/19), 12% (6/50), 16.7% (7/42), 14.3% (2/14),
and 0% (0/6) of cases for 𝑁0, 𝑁12, 𝑁24, 𝑁36, and 𝑁 > 36
groups, respectively. This subset of patients showed an active
replication of JCV in either plasma, urine, or both samples,
despite a negative serology for anti-JCV antibodies (Figure 1).
3.3. T-Lymphocyte Immunophenotyping. CD49d (𝛼4 inte-
grin) expression on CD4+ and CD8+ T-lymphocyte sub-
sets was evaluated by measuring the median fluorescence
intensity (MFI) with flow cytometry. CD49d expression on
the overall CD4+ and CD8+ T-lymphocytes was decreased
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Figure 1: Discordance between the Stratify JCV assay and JCV-DNA detection in blood and urine samples. The pie charts represent the
percentages of concordance and discordance between JCV antibody (Ab) and JCV-DNAdetection in urine and plasma. Percentages of double
positive JCV-DNA+ and JCV-Ab+ cases: 21% (4/19), 12% (6/50), 16.7% (7/42), 28.6% (4/14), and 33.3% (2/6) at 𝑁0, 𝑁12, 𝑁24, 𝑁36, and
𝑁 > 36, respectively. Percentages of JCV-DNA− and JCV-Ab+ cases: 21% (4/19), 18% (9/50), 23,8% (10/42), 21.4% (3/14), and 50% (3/6) of
cases at 𝑁0, 𝑁12, 𝑁24, 𝑁36, and 𝑁 > 36, respectively. Percentages of cases with double negative JCV-DNA− and JCV-Ab−: 36,8% (7/19),
58% (29/50), 42,9% (18/42), 35.7% (5/14), and 16.7% (1/6) of cases at𝑁0,𝑁12,𝑁24,𝑁36, and𝑁 > 36, respectively. Percentages of discordant
cases with JCV-DNA+ and JCV-Ab− (separated sector): 21.1% (4/19), 12% (6/50), 16.7% (7/42), 14.3% (2/14), and 0% (0/6) of cases at𝑁0,𝑁12,
𝑁24,𝑁36, and𝑁 > 36, respectively.𝑁0: 0 infusions,𝑁12: from 1 to 12 infusions,𝑁24: from 13 to 24 infusions,𝑁36: from 25 to 36 infusions,
and𝑁 > 36: over 36 infusions of natalizumab.
in patients with longer exposition compared to patients
with shorter or no exposition to natalizumab treatment
(Kruskal–Wallis test, 𝑝 = 0.0004 and 𝑝 = 0.01, resp.).
Specifically, CD49d MFI remained unchanged on CD4 and
CD8𝑁 subsets in all the groups, while it was found decreased
on CD4 and CD8 CM, EM, E, and CD8 I subsets of patients
with longer exposition compared to patients with shorter or
no exposition to natalizumab treatment (Kruskal–Wallis test,
for CD4 CM: 𝑝 ≤ 0.0001, CD4 EM: 𝑝 = 0.0022, and CD4 E:
𝑝 < 0.0001; for CD8 CM: 𝑝 < 0.0001, CD8 EM: 𝑝 < 0.0001,
CD8 E: 𝑝 < 0.0001, and CD8 I: 𝑝 < 0.0001) (Figure 2)
(Supplementary Table 2).
Analyzing CD8 subsets, we showed that CD8 N per-
centages were unchanged in the 5 groups, with median
values comparable with those observed in HD. Conversely
CD8 CM, EM, and E percentages increased in patients with
longer exposition compared to patients with shorter or no
exposition to natalizumab treatment (Kruskal–Wallis test, for
CD8 CM: 𝑝 = 0.02, CD8 EM: 𝑝 = 0.0003, and CD8 E: 𝑝 =
0.0057) (Figure 3(b)). No statistically significant differences
in CD4 subset percentages were observed in the 5 groups
(Figure 3(a)) (Supplementary Table 2). The assessment of T-
lymphocyte immune activation demonstrated an increment
of immune activated CD4+ and CD8+ cells in patients with
longer exposition compared to patients with shorter or no
exposition to natalizumab treatment (Kruskal–Wallis test,
𝑝 = 0.01 and 𝑝 = 0.003, resp.) (Figures 4(a) and 4(b)).
No statistically significant differences were found in immune
senescent CD4 and CD8 percentages (Figures 4(c) and 4(d)).
3.4. Relationship between CD8 E and JCV Replication. Con-
sidering that urine and blood were collected together for
each patient at each sampling time, 131 coupled samples were
obtained from 44 patients. Twenty-nine coupled samples
were JCV-DNA+ because of JCV-DNA detection in plasma
(JCVp+) while 13 coupled samples were JCV-DNA+ because
of JCV-DNA detection only in urine (JCVu+). Eighty-nine
coupled samples were JCV-DNA− because of JCV-DNA
undetectability in both plasma and urine. After comparing
the JCVp+, JCVu+, and JCV-DNA− groups, the percentage
of CD8 E was increased in the JCVp+ and JCVu+ compared
to the JCV-DNA− group and the differences were statistically
significant (Kruskal–Wallis test, 𝑝 = 0.0001) (Figure 5(a)).
Given the evidence of increased CD8 E percentages
associated with JCV-DNA positivity in plasma and urine,
the Receiving Operator Curve (ROC) was calculated and a
cut-off of 10.6% for CD8 E was found, indicating that CD8
E percentages greater than 10.6% were predictive of JCV-
DNA detection in either plasma, urine, or both samples
(Figure 5(b)).
After stratifying the samples according to natalizumab
infusion number, higher levels of CD8 E were associated
with JCV-DNA detection in plasma or urine, for 𝑁12
(Mann–Whitney, 𝑝 = 0.002) and 𝑁24 groups (Mann–
Whitney,𝑝 < 0.0001). Although similar resultswere obtained
for𝑁36 and𝑁 > 36 groups, the differences did not reach the
statistical significance (Figure 6).
These data were further analyzed, considering JCV
serostatus and stratifying samples according to JCV serology
in JCV-Ab+ and JCV-Ab−. Notably, the results previously
shown for the whole cohort were confirmed for both groups
of JCV-Ab+ and JCV-Ab− patients (Mann–Whitney, 𝑝 <
0.001 and𝑝 = 0.004, resp.) (Figure 7(a)). Interestingly, CD8 E
percentages were found significantly increased in JCV-Ab+ as
well as JCV-Ab− patients with detectable JCV-DNA in urine
or plasma, for 𝑁12 and 𝑁24 groups (Mann–Whitney, 𝑝 =
0.049 and𝑝=0.0012 for JCV-Ab+;𝑝=0.004 and𝑝=0.008 for
JCV-Ab−, resp.) (Figures 7(b) and 7(c)).
4. Discussion
Our results confirmed the presence of a subset of patients
with negative JCV serology (indicating the lack of anti-JCV
specific IgG) despite the detection of viral DNA in blood or
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Figure 2: CD49d median fluorescence intensity (MFI) measured on CD4+ and CD8+ T-lymphocyte subsets. CD49d expression assessed on the
overall CD4+ (a) and CD8+ (b) T-lymphocytes and their subpopulations in peripheral blood of RRMS patients under natalizumab treatment
are represented after stratification according to natalizumab infusion number. Statistical analysis was performed using a one-way ANOVA
test for nonparametrical data (Kruskal–Wallis): for CD4, 𝑝 = 0.0004; CD4 N, 𝑝 > 0,05; CD4 CM, 𝑝 < 0,0001; CD4 EM, 𝑝 = 0.0022; CD4 E,
𝑝 < 0.0001; for CD8, 𝑝 = 0.01; CD8 I, 𝑝 < 0.0001; CD8 N, 𝑝 > 0.05; CD8 CM, 𝑝 < 0.0001; CD8 EM, 𝑝 < 0.0001; CD8 E, 𝑝 < 0.0001. Dunnett’s
posttest was performed comparing each group with 𝑁0, and asterisks represent the level of statistical significance. Dashed line represents
median value of CD49d expression observed in healthy donors. CD49d expression on CD4+ and CD8+ T-lymphocytes decreased from𝑁0
to𝑁 > 36 group with a linear trend (posttest for linear trend: 𝑝 < 0,0001 and 𝑝 = 0,0035, resp.). Lines and whiskers represent median values
and interquartile ranges, respectively. N: na¨ıve, CM: central memory, EM: effector memory, E: effectors, I: intermediate. 𝑁0: 0 infusions,
𝑁12: from 1 to 12 infusions, 𝑁24: from 13 to 24 infusions, 𝑁36: from 25 to 36 infusions, and 𝑁 > 36: over 36 infusions of natalizumab.
∗0.05 < 𝑝 < 0.01; ∗∗0.01 < 𝑝 < 0.001; ∗∗∗𝑝 < 0.001; ∗∗∗∗𝑝 < 0.0001.
urine. Other authors reported similar results, suggesting that
JCV serology alone is not sufficient for the diagnosis of JCV
infection and should be associated with JCV-DNA detection
in body fluids (such as blood or urine) in order to truly iden-
tify JCV infected patients [25, 26]. Possible explanations for
this discordance could be the occurrence of acute infection at
sampling time, when IgG are still absent despite a replicating
virus, or the presence of a low IgG titer, not detectable by the
Stratify JCV assay [25]. Second-generation Stratify JCV assay
showed an increased sensitivity, detecting anti-JCV specific
antibodies in previously negative patients [27]. Despite this
improvement, some patients still have a detectable JCV-
DNA in urine or blood with a negative JCV serology. Some
authors described the occurrence of PML in RRMS patients
receiving natalizumab with a negative JCV serology [28],
thus underlining the need for a more accurate evaluation
of those patients who should start or are already receiving
a treatment with natalizumab, by using different methods
to directly or indirectly detect prior JCV infection. In this
study we observed that CD49d expression tends to decrease
on T-lymphocytes in parallel with the increase in natal-
izumab infusion number. This result was already reported
in previous works from our and other groups [17, 29].
Notably, in this work we adopted a cross-sectional approach,
demonstrating that CD49d expression can be used as a
marker of natalizumab exposure. Furthermore, the decrease
in CD49d expression on T-lymphocytes was inversely related
to natalizumab infusion number, following a linear trend.
CD49d expression has been already proposed as a useful
tool for monitoring natalizumab efficacy, especially in those
patients who become refractory to treatment, because of the
development of anti-natalizumab antibodies. Indeed, anti-
natalizumab antibody production was associated with an
increase in CD49d expression after an initial decrement
[29]. Recently, the evaluation of CD49d receptor occupancy
with flow cytometry has been considered as a method to
optimize and personalize natalizumab treatment in RRMS
patients [30]. As a consequence of the decreased CD49d
expression on the cell surface, we observed a modification of
CD8 subset distribution, with accumulation of CD8 central
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Figure 3: Evaluation of T-lymphocyte subset percentages in blood samples. Percentages of CD4+ (a) and CD8+ (b) T-lymphocyte
subpopulations in peripheral blood of RRMS patients under natalizumab treatment are represented, after stratification according to
natalizumab infusion number. Values are represented as percentage of the parental population (overall CD4 and CD8, resp.). Statistical
analysis was performed using a one-way ANOVA test for nonparametrical data (Kruskal–Wallis, for CD4 N, 𝑝 > 0.05; CD4 CM, 𝑝 > 0.05;
CD4 EM, 𝑝 > 0.05; CD4 E, 𝑝 > 0.05; CD8 N, 𝑝 > 0.05; CD8 I, 𝑝 > 0,05; CD8 CM, 𝑝 = 0.02; CD8 EM, 𝑝 = 0.0003; CD8 E,
𝑝 < 0.0057). Dunnett’s posttest was performed comparing each group with 𝑁0, and asterisks represent the level of statistical significance.
Lines and whiskers represent median values and interquartile ranges, respectively. Dashed line represents median percentages observed in
healthy donors. N: na¨ıve, CM: central memory, EM: effector memory, E: effectors, and I: intermediate. 𝑁0: no infusions, 𝑁12: from 1 to 12
infusions, 𝑁24: from 13 to 24 infusions, 𝑁36: from 25 to 36 infusions, and 𝑁 > 36: over 36 infusions of natalizumab. ∗0.05 < 𝑝 < 0.01;
∗∗0.01 < 𝑝 < 0.001; ∗∗∗𝑝 < 0.001; ∗∗∗∗𝑝 < 0.0001.
memory, effector memory, and effector subsets in peripheral
blood. Similar results have been previously shown with a
longitudinal approach in natalizumab treated RRMS patients
[17, 22]. Furthermore, CD4/CD8 ratio was found decreased
in patients under natalizumab treatment with a negative
correlation with JCV antibody index [22]. Planas et al.
showed an increase in peripheral blood lymphoid progenitor
percentages and B- and T-lymphocyte absolute counts of
RRMS patients after natalizumab treatment, although they
did not find any difference in CD4 and CD8 subset dis-
tribution and CD4/CD8 ratios. These differences could be
due to the heterogeneity of the cohorts, considering that,
for instance, in our study, patients were younger and had
lower EDSS values compared to those enrolled in Planas
et al. study [31]. In a previous work in which 26 RRMS
patients under natalizumab treatment were longitudinally
followedup for 24months, we showed thatCD8E is increased
in patients with detectable JCV-DNA in plasma or urine
[17]. The present work corroborates our previous results,
demonstrating similar findings in a larger cohort of patients
and adopting a cross-sectional approach for data analysis.
CD8 E tended to increase in RRMS patients treated with
natalizumab and also increased in patients with JCV-DNA
detection in plasma or urine. This finding indicates a poten-
tial role of these cells during JCV reactivation. Memory and
effector CD8 subset accumulation in peripheral blood, due to
natalizumab administration, should reflect their reduction in
the CNS [32], with an impairment of immune-surveillance
mechanisms. It has been shown that low CD8 counts may
increase the risk of PML, because JCV containment appears
to be more strongly related to CD8+ T-lymphocyte activity
[33]. Moreover, dimethyl fumarate (another effective treat-
ment for RRMS) causes significantly sustained reduction in
CD8+ T-lymphocyte counts and, to a lesser extent, CD4+
T-lymphocyte counts [34, 35]. Gieselbach et al. showed that
in 19 PML cases observed in patients treated with fumaric
acid esters, low CD8 and CD4 cell counts were associated
with increased risk of developing PML [36]. Although we
did not observe any case of natalizumab-induced PML in
this cohort of patients, we analyzed the association between
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Figure 4: Immune activation and immune senescence levels of CD4+ and CD8+ T-lymphocytes. (a) CD4+ T-lymphocyte immune activation
levels were assessed considering the percentages of HLA-DR and CD38 double positive CD4. 𝑁0: 1.6% [0.9–1.8], 𝑁12: 1.6% [0.9–2.3],
𝑁24: 1.7% [1.3–2.2], 𝑁36: 2.7% [1.6–3.2], and 𝑁 > 36: 2.1 [1.8–2.4]. Statistical analysis was performed using a one-way ANOVA test for
nonparametrical data (Kruskal–Wallis,𝑝= 0.0099). Dunnett’s posttest was performed comparing each groupwith𝑁0, and asterisks represent
the level of statistical significance. Dashed line represents median value of CD4+ T-lymphocyte immune activation levels observed in healthy
donors. (b) CD8+ T-lymphocyte immune activation levels were assessed considering the percentages of HLA-DR and CD38 double positive
CD8.𝑁0: 1.5% [1.0–1.9],𝑁12: 2.3% [1.4–4.7],𝑁24: 2.7% [1.7–4.8],𝑁36: 3.6% [2.3–4.3], and𝑁 > 36: 3.0% [2.0–5.2]. Statistical analysis was
performed using a one-wayANOVA test for nonparametrical data (Kruskal–Wallis,𝑝= 0.0025). Dunnett’s posttest was performed comparing
each group with𝑁0, and asterisks represent the level of statistical significance. Dashed line represents median value of CD8+ T-lymphocyte
immune activation levels observed in healthy donors. Immune senescence levels were evaluated for CD4+ (c) and CD8+. (d) T-lymphocytes
as the percentages of CD28 negative and CD57 positive cells. No statistical significant differences were found after performing a one-way
ANOVA test for nonparametrical data (Kruskal–Wallis). Lines and whiskers represent median values and interquartile ranges, respectively.
𝑁0: no infusions,𝑁12: from 1 to 12 infusions,𝑁24: from 13 to 24 infusions,𝑁36: from 25 to 36 infusions, and𝑁 > 36: over 36 infusions of
natalizumab. ∗0.05 < 𝑝 < 0.01; ∗∗0.01 < 𝑝 < 0.001; ∗∗∗𝑝 < 0.001; ∗∗∗∗𝑝 < 0.0001.
CD8 subset modifications and JCV reactivation. Here we
confirmed previous results [17], demonstrating that CD8
E percentages were increased in patients with detectable
JCV-DNA in urine and plasma. Moreover, we found a cut-
off value for CD8 E percentages of 10.6%, which means
that CD8 E percentages above this value were strongly
associated with JCV-DNA detection. After stratifications of
RRMS patients according to natalizumab infusion number,
we demonstrated that the combined effect of natalizumab
and JCV replication determined an increase in CD8 E
percentages, with statistically significant differences in the
𝑁12 and 𝑁24 groups, while no differences were observed
for 𝑁0 group (before natalizumab administration). Finally,
after stratifying the patients according to JCV serology, CD8
E percentages were found to be increased, in association with
JCV-DNA detection in urine or plasma, in patients with JCV
positive as well as negative serology, indicating that CD8 E
percentages increase in parallel with JCV-DNA detection,
independently from anti-JCV serostatus. Some limitations of
our study were the fact that we did not observe any case of
natalizumab-induced PML and that we did not evaluate the
specificity of CD8 subsets, which accumulate in peripheral
8 BioMed Research International
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Figure 5: CD8 E percentages according to JCV-DNA detection in biological samples and ROC analysis. (a) CD8 E percentages associated
with JCV-DNA positive urine samples (JCVu+), JCV-DNA positive plasma samples (JCVp+), and JCV-DNA negative plasma and urine
samples (JCV-DNA−) are shown: for JCVu+, 13.4% [7.6–15.4], for JCVp+, 13.2% [8.3–15.2], and for JCV-DNA−, 8.0% [6.0–12.0]. Data
are represented as median [interquartile range]. Statistical analysis was performed using a one-way ANOVA test for nonparametrical data
(Kruskal–Wallis, 𝑝 = 0.0001). Dunnett’s posttest was performed comparing each group with JCV-DNA− group, and asterisks represent
the level of statistical significance. (b) ROC analysis was performed using CD8 E percentages after stratification of samples according to
JCV detection in plasma and/or urine in JCV-DNA+ and JCV-DNA−. The area under the curve is 0.73 with 𝑝 < 0.0001. The cut-off of
>10.6% shows a sensitivity of 67% (CI: 51% to 80%) and a specificity of 65% (CI: 54% to 75%). CI: confidence interval. Lines and whiskers
represent median values and interquartile ranges, respectively. CD8 E: CD8 effectors. ∗0.05 < 𝑝 < 0.01; ∗∗0.01 < 𝑝 < 0.001; ∗∗∗𝑝 < 0.001;
∗∗∗∗𝑝 < 0.0001.
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Figure 6:CD8E percentages in JCV-DNA+and JCV-DNA− samples, after stratification according to natalizumab infusion number. Comparison
of CD8 E percentages between JCV-DNA+ (plasma and/or urine) and JCV-DNA− samples for 𝑁0: 6.6% [3.8–11.9] versus 5.1% [1.9–9.5],
𝑁12: 14.7% [12.4–16.9] versus 11.1% [6.8–13.6],𝑁24: 13.6% [11.8–16.2] versus 8.0% [4.6–10.8],𝑁36: 9.5% [7.0–14.8] versus 8.1% [6.5–9.7],
and 𝑁 > 36: 12.5% [11.3–13.7] versus 6.7% [6.4–7.4]. Data are shown as median [interquartile range]. Statistical analysis was performed
using the 2-tailed Mann–Whitney test (𝑝 = 0.3, 𝑝 = 0.002, 𝑝 < 0.0001, 𝑝 = 0.2, and 𝑝 = 0.1, for 𝑁0, 𝑁12, 𝑁24, 𝑁36, and 𝑁 > 36, resp.).
Lines and whiskers represent median values and interquartile ranges, respectively. CD8 E: CD8 effectors. 𝑁0: no infusions, 𝑁12: from 1 to
12 infusions, 𝑁24: from 13 to 24 infusions, 𝑁36: from 25 to 36 infusions, and 𝑁 > 36: over 36 infusions of natalizumab. ∗0.05 < 𝑝 < 0.01;
∗∗0.01 < 𝑝 < 0.001; ∗∗∗𝑝 < 0.001; ∗∗∗∗𝑝 < 0.0001.
blood after natalizumab treatment. Functional studies involv-
ing peripheral blood CD8 subsets, after stimulation with JCV
specific peptides, could give more information about their
specificity and the ability to produce cytokines and perform
cytotoxicity.
5. Conclusion
The most important finding of this study is that, in natal-
izumab treated RRMS patients, independently from JCV
serology, CD8 E percentages were found increased in those
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Figure 7:CD8 E percentages in JCV-DNA+ and JCV-DNA− samples, after stratification according to anti-JCV specific serology and natalizumab
infusion number. (a) Comparison of CD8 E percentages between JCV-DNA+ (plasma and/or urine) and JCV-DNA− samples in patients
with either positive or negative JCV serology (JCV-Ab+ and JCV-Ab−, resp.). For JCV-Ab+, 13.4% [8.2–14.8] versus 7.8% [6.2–9.9]; for
JCV-Ab−, 13.2% [7.1–16.2] versus 8.2% [5.8–12.7], respectively. Data are shown as median [interquartile range]. Statistical analysis was
performed using the 2-tailed Mann–Whitney test (𝑝 = 0.0007 and 𝑝 = 0.004 for JCV-Ab+ and JCV-Ab− groups, resp.). (b) Comparison of
CD8 E percentages between JCV-DNA+ (plasma and/or urine) and JCV-DNA− samples in patients with positive JCV serology (JCV-Ab+),
after stratification according to natalizumab infusion number: for𝑁0: 6.4% [2.8–12.1] versus 7.0% [2.5–12.3],𝑁12: 14.1% [8.4–15.7] versus
7.8% [6.5–11.8],𝑁24: 13.4% [12.6–16.1] versus 7.3% [2.8–8.8],𝑁36: 11.3% [7.2–15.8] versus 10.2% [8.1–23.2], and𝑁 > 36: 12.5% [11.3–13.7]
versus 6.5% [6.4–6.8]. Data are shown as median [interquartile range]. Statistical analysis was performed using the 2-tailed Mann–Whitney
test (𝑝 = 0.8, 𝑝 = 0.049, 𝑝 < 0.0012, 𝑝 = 0.86, and 𝑝 = 0.2, for𝑁0,𝑁12,𝑁24,𝑁36, and𝑁 > 36, resp.). (c) Comparison of CD8 E percentages
between JCV-DNA+ (plasma and/or urine) and JCV-DNA− samples in patients with negative JCV serology (JCV-Ab−), after stratification
according to natalizumab infusion number: for𝑁0: 6.6% [4.2–11.6] versus 5.1% [1.4–6.2],𝑁12: 15.4% [13.8–18.8] versus 12.0% [6.7–13.7],
𝑁24: 13.8% [9.2–16.8] versus 8.4% [4.9–11.3], 𝑁36: 8.9% [7.1–10.8] versus 6.6% [6.1–8.2], and 𝑁 > 36: not applicable. Data are shown as
median [interquartile range]. Statistical analysis was performed using the 2-tailed Mann–Whitney test (𝑝 = 0.2, 𝑝 = 0.004, 𝑝 < 0.008,
𝑝 = 0.38, and 𝑝 = not applicable, for𝑁0,𝑁12,𝑁24,𝑁36, and𝑁 > 36, resp.). Lines and whiskers represent median values and interquartile
ranges, respectively. CD8 E: CD8 effectors. 𝑁0: no infusions, 𝑁12: from 1 to 12 infusions,𝑁24: from 13 to 24 infusions, 𝑁36: from 25 to 36
infusions, and𝑁 > 36: over 36 infusions of natalizumab. ∗0.05 < 𝑝 < 0.01; ∗∗0.01 < 𝑝 < 0.001; ∗∗∗𝑝 < 0.001; ∗∗∗∗𝑝 < 0.0001.
subjects with JCV replication, as assessed by viral DNAdetec-
tion in plasma or urine samples. Moreover, the evaluation of
CD8 E could help in detecting JCV reactivation, especially
in JCV seronegative patients, who are currently considered at
lower risk of developing PML during natalizumab treatment.
Larger cohorts are needed in order to verify these results and
further studies should be performed in order to understand
the pathological and clinical significance of CD8 subset
modifications associated with natalizumab administration
and their relationship with JCV reactivation and PML onset.
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